Why the study?
While interactions and clinical outcomes of PPIs and DAPT are frequently explored, few studies have evaluated these outcomes for triple therapy following PCI.
Does the addition of proton pump inhibitors to triple therapy reduce gastrointestinal bleeding in patients with atrial fibrillation following percutaneous coronary intervention?
Does the addition of proton pump inhibitors to triple therapy reduce gastrointestinal bleeding in patients with atrial fibrillation following percutaneous coronary intervention?
In patients with atrial fibrillation undergoing PCI who require triple therapy, adding a PPI, particularly alongside apixaban, may help mitigate the high risk of gastrointestinal bleeding.
Answers are grounded in this paper and cite their sources.
PPI gastroprotection in triple therapy post-PCI requires individualized risk assessment; leaves open optimal agent selection pending dedicated outcome studies.
INTRODUCTION: Patients on systemic oral anticoagulation with vitamin K antagonists (VKA) or non-vitamin K oral anticoagulants (NOAC) often require triple therapy following percutaneous coronary intervention, substantially increasing the risk of bleeding. Gastroprotective agents like proton pump inhibitors (PPI) are often employed to mitigate this risk, despite potential competitive inhibition between P2Y12-receptor inhibitors, NOACs, and VKAs. While the interactions and clinical outcomes of PPIs and DAPT have been frequently explored in literature, not many studies have evaluated the same outcomes for triple therapy. AREAS COVERED: This comprehensive narrative review of three studies on PPIs and triple from the PubMed/MEDLINE database supplemented by 23 other relevant studies aims to use the available literature to analyze the potential interactions between PPIs and triple therapy while shedding light on their mechanisms, clinical implications, and areas for optimization. EXPERT OPINION: If triple therapy is indicated following PCI, then patients at high-risk for bleeding may benefit from transition to apixaban and a PPI to lower the risk of gastrointestinal bleeding. More research is needed to determine the role of PPIs in triple therapies in prevention of gastrointestinal bleeding or potentiation of other adverse outcomes.
No takes yet. Share an insight, caveat, or question.
Gries et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: